Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2013

View Archived Issues

Several microRNAs elevated in serum after ischemic stroke

Recombinant allergen therapy for patients with birch pollen allergy

CDK4/6 inhibitor LY-2835219: first-in-human study

Genor Biopharma and BioCND to develop biosimilars of Humira and Herceptin

New MR/GR agonists synthesized by Allergan

GS-444217 demonstrates efficacy in model of PAH

AQX-1125 evaluated in patients with asthma

Novel COL8A2 gene mutations found in Korean patients with FECD

Proteostasis Therapeutics receives Michael J. Fox Foundation grant

Genoa Pharmaceuticals's inhaled pirfenidone shows antifibrotic efficacy

Idera begins dosing in phase II IMO-8400 study

Receptos presents update on RPC-1063

Andromeda reports on extension study of the phase III DIA-AID1 trial

Aliskiren and VTP-27999 show different effects of on human renin and prorenin

Positive results obtained from phase III aflibercept study in mCNV

PXS-4728 as a novel SSAO inhibitor with in vivo anti-inflammatory activity

RXi Pharmaceuticals reports results from phase I RXI-109 study

CytomX and Pfizer to develop Probody-Drug Conjugates for cancer

Actelion Pharmaceuticals presents new OX1 receptor antagonists

Novel DNA topoisomerase II inhibitors patented by the University of Colorado

BioLineRx enrolls first patient in phase II BL-8040 study

Lipaglyn obtains approval in India for diabetic dyslipidemia

Sunovion Pharmaceuticals synthesizes new mu opioid receptor agonists

Novel NS5B inhibitors presented for hepatitis C virus infection

RedHill begins patient screening in phase IIa combination therapy for RRMS

Medicago reports interim data from preclinical trial of its H7N9 vaccine